

New and Emerging Therapies in Myelofibrosis

References

1. Karyopharm initiates pivotal phase 3 study of XPO1 inhibitor selinexor and ruxolitinib in JAK inhibitor (JAKi) naïve myelofibrosis. News release. Karyopharm Therapeutics Inc. June 28, 2023. Accessed October 25, 2023. <https://shorturl.at/emWY0>
2. Mascarenhas J, Kremyanskaya M, Patriarca A, et al. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. *J Clin Oncol*. 2023 Mar 7:JCO2201972.
3. Pemmaraju N, Garcia JS, Potluri J, et al. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. *Lancet Haematol*. 2022 Jun;9(6):e434-e444.
4. Passamonti F, Foran JM, Tandra A, et al. The combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis mediates responses suggestive of disease modification. *Blood*. 2022;140(Suppl 1):583-585.
5. Pullarkat V, Cruz-Chacon A, Gangatharan S, et al. P1070: navitoclax monotherapy in patients with myelofibrosis previously treated with JAK-2 inhibitors: safety and tolerability. *HemaSphere*. 2022;6:960–961.
6. Mascarenhas J, Komrokji RS, Palandri F, et al. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. *J Clin Oncol*. 2021 Sep 10;39(26):2881-2892.
7. Mascarenhas J, Harrison C, Kiladjian JJ, et al. MYF3001: a randomized open label, phase 3 study to evaluate imetelstat versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis relapsed/refractory to janus kinase inhibitor. *Blood*. 2022;140(Suppl 1):6826-6829.
8. Pettit KM, Gill H, Yacoub A, et al. A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses. *Blood*. 2022;140(Suppl 1):9717-9720.
9. Mascarenhas J, Jain T, Otoukesh S, et al. An open-label, global, phase (Ph) 1b/2 study adding navtemadlin (NVTM) to ruxolitinib (RUX) in patients (Pts) with primary or secondary myelofibrosis (MF) who have a suboptimal response to RUX. *HemaSphere*. 2023;7(suppl 3):S210.

Provided by MediCom Worldwide, Inc.

Supported by educational grants from Constellation Pharmaceuticals Inc., A MorphoSys Company, CTI BioPharma Corp., Incyte Corporation, and Karyopharm Therapeutics Inc.